Investors

Biography

Saniona Icon blue
Rudolf Baumgartner

Rudolf Baumgartner

Chief Medical Officer and Head of Clinical Development

Rudolf Baumgartner (born 1959) is a physician-scientist with a proven track record of leading cross-functional teams through multiple development programs from Investigational New Drug (IND) applications through New Drug Application (NDA) submissions and product approvals. Trained in basic immunology, he has significant expertise across a broad array of therapeutic areas, including inflammation and autoimmune diseases.

Prior to joining Saniona, Baumgartner served as Chief Medical Officer for the Flatley Discovery lab, a non-profit foundation working in the rare disease space of Cystic Fibrosis. Prior to that, he was the Executive Vice President and Chief Medical Officer for Inotek Pharmaceuticals, where he was instrumental in writing the S1 and co-leading the company’s IPO. At Inotek, he oversaw clinical development and operations, medical affairs, regulatory affairs, biostatistics, preclinical development, and intellectual property. Before Inotek, Baumgartner held senior-level development positions at Sepracor and Merck & Co. He began his medical career as a clinician-scientist at the National Institutes of Health (NIH), in the Laboratory of Molecular Immunology at the National Heart, Lung, and Blood Institute (NHLBI). He completed his MD at Pennsylvania State University, his residency in Internal Medicine at the University of Michigan, and his fellowship in Pulmonary and Critical Care Medicine at Johns Hopkins University.

Baumgartner holds 8,300 shares and 829,512 options in the options program 2020/2031.